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Abstract 
BACKGROUND: The nucleotide changes in different genetic loci increased the incidence risk of breast cancer.  
AIM: The aim of present study was to investigate genotype distribution at codon 72 of the TP53 gene (rs1042522) 
in breast cancer patients to achieve a potential diagnostic marker related to some demographic feathers.  
METHODS: In our case-control study, blood samples were collected from a total of 34 patients harboured breast 
cancer. DNA was extracted, and nested-PCR was performed. Products were digested with AccII and 
subsequently were sequenced. Results were compared with samples characteristics. 
RESULTS: The PCR results indicated the correct implementation of extraction and amplification protocol. The 
genotypic distribution at codon 72 of TP53 in control group was 20%, 62.4% and 16.6% for Arg (wildtype), Arg/Pro 
(heterozygous) and Pro (homozygous variant) respectively. Also, this distribution in the patient group was 23.52% 
homozygous, 50% heterozygous, and 26.47% another homozygous variant (Adjusted odds ratio: 1.12 and 95%CI 
= 0.57 to 2.2, P = 0.03). The absence of Arg at codon 72 of TP53 is relevant with age higher than 40 years and 
metastasis to other organs. 
CONCLUSION: Polymorphism at codon 72 of TP53 was associated with high-grades of breast cancer risk and 
different responses to chemotherapy treatment. It is recommended genotype distribution of codon 72 of TP53 
before chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer (BC) is one of the most 
common types of cancer that causes mortality rates 
each year. Despite advances in early diagnosis and 
proper treatment for this disease, it remains the main 
cause of death among women [1], [2], [3]. The most 
common sites of BC metastasis are bones, lunge and 
liver. Metastasis of BC to the brain less occur. The 
growth of cancer cells in BC is considered in three 
stages. BCs stage I or II are in the initial stage. If the 
tumour extends to the underlying muscles of the chest 
wall or skin, BC is type III. This Stage also includes 
BCs involving inflammatory system, in which case the 
breast is red or swollen [4], [5], [6]. BC stage IV refers 
to tumours that metastasise to the outside of the 
breast and the lymph nodes, as well as to the brain, 
bones, skin, and other organs. The basics of cancer 
genetics is the occurrence of changes in signalling 
pathways and genes regulatory networks [5]. 
Changes in different codons of the genes, including 
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BRCA1, BRCA2, and TP53 etc. increase the risk of 
developing breast cancer. In some cases due to a 
mutation in TP53, the occurrence of BC can be 
accompanied by brain tumours and leukaemia. TP53 
(also known as BCC7, LFS1) is a TSG. This gene is 
encoded on the human chromosome 17 at position 
p13.1 (HGNC ID: 11998). Different transcripts are 
reported for this gene (Figure 1). Some of these 
transcripts are not protein coding 
(ENSG00000141510). This gene is very important in 
the coordination of the cell cycle as well as in 
preventing the development of cancer [2].  
 
Figure 1: View of the TP53 chromosome position and the Ensemble 
databank of variants and SNPs of the TP53 gene. The codon 72 is 
shown by the blue arrow 
 
In addition, the TP53 gene has a variety of 
anti-cancer activities, such as apoptosis, genome 
stability (preventing the appearance of mutation in the 
genome) and preventing angiogenesis [3]. P53 
Protein plays a major role in the initiation of apoptosis. 
The amount of P53 protein increases when the cell is 
exposed to stress [3], [6]. The defects in DNA repair 
are often the result of mutations, which may lead to 
the loss of DNA repairing proteins activity. DNA 
polymorphisms may also alter the structure of 
repairing enzymes and reduce their repair ability. Key 
polymorphisms in some genes, including TP53, may 
increase the risk of BC and may lead to a difference in 
treatment. Several SNPs have been recorded for this 
gene. One of these polymorphisms is the nucleotide 
change in codon 72 of this gene which can lead to a 
missense amino acid residue conversion Arg (CGC) 
to Pro (CCC). Rs1042522 is one of 25 important 
SNPs reported to increased risk for BC [7]. The G and 
C of this polymorphism allele encode an Arg and Pro 
respectively at position 72 of the P53. It has been 
reported that alteration of this codon is likely to be 
associated with an increased risk of some of the 
diseases [8], [9], [10], [11]. This association is related 
to population type. African population with two copies 
of G (G;G) in rs1042522 in TP53 were 2.15 times 
more susceptible to die due to rectal cancer than 
those with (C;G) or (C;C) at mentioned polymorphism. 
Also in Caucasians, there was no association 
between survival and rs1042522. In Asadi et al., study 
were detected no association between rs1042522 C > 
G polymorphism and Risk of Colorectal Cancer in the 
Iranian Azari Population [12]. In his another study, 
also was detected No association between rs1042522 
C > G SNP and neuroblastoma risk using TaqMan 
genotyping [13]. There has been no report on the 
relationship between the rs1042522 polymorphism in 
TP53 and tumour grade, age, Body mass index (BMI) 
and the response rate to chemotherapy in BC patients 
of Markazi province of Iranian population. The aim of 
present study was to evaluate the polymorphism at 
codon 72 of TP53 in patients with BC and investigate 
the relationship between genotype distributions with 
above factors in patients with BC in aforementioned 
Iranian population.  
 
 
Materials and Methods 
 
In present case-control study, samples were 
collected from Ayatollah-Khansari hospital in Arak city. 
This study was performed between November 2016 
and June 2017. A total of 34 pathological and clinical 
data were classified for the collected breast cancer 
samples (median age: 48 years). Also, normal 
samples from non-tumour individuals were equal 
numbers of patients group. Three ml of blood was 
collected from each sample in CBC test vial. The 
study was approved by the Research Ethics 
Committee of Arak University of Medical Sciences 
(Ethics number 618B/3090). Participants of present 
study agreed with and signed a consent form.  
DNA extraction was performed from 500 μl 
whole blood using the Diatom DNA Kit (IsoGene, 
Moscow, Russia) based on its instruction. Samples 
were loaded on 1% agarose gel, (YTA, Iran).  
In Polymerase chain reaction, 50 mM MgCl2 
(Cinagene, Iran), 10X Buffer (Cinagene, Iran), 10 mM 
dNTP (Cinagene, Iran), 1unit Taq polymerase 
(Cinagene, Iran), and specific primers at a suitable 
concentration of 10 pmol were used. Annealing 
temperature for the primers [9] was optimised at 
52.7°C. 
In this study, PCR products of the first stage 
were used in a thermocycler machine (Eppendorf, 
Germany) as a template in the second stage PCR 
using a pair of internal primers in order to more 
specificity and enhancing the amplified bands. A non-
template sample was used as a negative control. The 
sequence of these primers is shown in Table 1. 
Table 1: The used primer sequence in this study 
Primer ID Sequence (5'-3') 
p53 F  GCTCTTTTCACCCATCTACAG 
p53 R  TGAAGTCTCATGGAAGCCAGC 
P53 Inner-F  TCCCCCTTGCCGTCCCAA 
P53 Inner-R  CGTGCAAGTCACAGACTT 
 
Restriction enzyme digestion was performed 
by AccII (Vivantis, Malasia) at 37°C for 3-16 hours. 
Production of one fragment of 300bp indicated the 
presence of the wildtype allele (Arg). The presence of 
the variant allele (Pro) was determined by the 
observation of two fragments of 160 bp and 140bp. 
The produced amplicons were sent for sequencing. 
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The sequencing was carried out with the ABI Applied 
Biosystem machine-Model 3730XL (Macrogene, 
South Korea). Sequencing results were analysed 
using Chromas, Mega 4.0, Blast and Blat software. 
Validation of genotypes was evaluated by 
comparison of sequences results with data banks 
such as UCSC. Chi-sq Hardy-Weinberg equilibrium 
(HWE) test calculator were used for biallelic markers 
including SNPs. The difference between the groups 
was determined by one-way ANOVA GraphPad prism 
7.0. P values less than 0.05 were considered 
statistically significant. 
 
 
Results 
 
The results of the amplification reaction 
indicated the accurate of the extracted DNA, the 
correct implementation of the temperature protocol 
and used primers. Figure 2 shows the 300bp amplicon 
of the TP53 gene. 
 
Figure 2: Steps of Nested-PCR steps in this study. The yellow arrow 
shows the 300 bp amplicon of TP53 gene 
 
In below figure columns 1-4 indicated bands 
of heterozygous samples that have three bands (300, 
160 and 140 bp). Also, Figure 3b shows the sequence 
analysis of the 8 homozygous amplicons. 
 
Figure 3: A) Agarose gel of digestion reaction. Column 1-4 showed 
heterozygote samples (Arg/Pro) and column 5 showed a 
homozygote wildtype (Arg); B) Nucleotide sequences from the 
sequencing of clinical samples (Chromas and Mega4 software) 
 
The genotypic distribution in the patient group 
was 23.52% homozygous wildtype (Arg), 50% 
heterozygous (Arg/Pro), and 26.47% another 
homozygous variant (Pro). These genotypes in the 
control group were 20%, 62.4% and 16.6% for 
homozygous wildtype, heterozygous and homozygous 
variant respectively.  
The C allele freq = 0.48; G allele freq = 0.52 
was the frequency of changes in codon 72 of the 
TP53 gene in patient group (HWE calculator, p < 
0.05). The Chi-square in control group was not 
significant (X2 = 6.8, p > 0.05).  
Table 2: different patterns from digestion reaction using MboII 
enzyme 
P 
value 
%99 
CI 
%95 CI %90 CI Odds 
Ratio 
Patients 
(%) 
Genotype Band (bp) Pattern of 
RFLP 
< 0.05 0.46-
2.72 
0.57-2.2 0.64-1.98 1.12 23.52 GG 
homozygote 
300 Pattern A 
< 0.05 0.51-
2.23 
0.61-
1.87 
0.66-1.71 1.07 50 CG 
heterozygote 
300, 160, 
140 
Pattern B 
< 0.05 0.57-
3.48 
0.71-2.8 0.79 -2.51 1.41 26.47 CC 
homozygote 
160, 140 Pattern C 
 
The Figure 4 showed that there are a 
significant association between the changing at codon 
72 (Arg72 Pro) of TP53 gene sequences and the Age 
> 40, BMI > 22, WHR > 0.8, metastasis to other 
organs, positive ER and PR status and less response 
to chemotherapy in BC samples than the control 
group. These associations are statistically significant. 
 
Figure 4: A) This chart shows the relationship between amplicons 
sequences and the characteristics of the used clinical samples; B) 
GraphPad Prism 7.0 software showed association between the Pro 
at codon 72 of TP53 gene and the Age > 40, BMI > 22, WHR > 0.8 
and negative response to chemotherapy (One-way ANOVA test, P 
= 0.03)  
 
 
Discussion  
 
The incidence rates of BC increase with an 
ascending trend so that its frequency has doubled 
over the past 20 years. In Iran, BC is the most 
common type of cancer after stomach and 
oesophagus cancers. Therefore, diagnosis at first 
stages and study of the molecular mechanisms of BC 
are necessary [1], [2], [3]. Molecular events that 
regulate cell survival, apoptosis, growth and 
differentiation of the cell, played an important role in 
the overall kinetics of tumour growth as benign or 
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malignant [14]. Mutation of TP53 is the most common 
genetic change in human cancers and is associated 
with poor response to treatment including 
chemotherapy and radiotherapy. Recent studies have 
shown the probably beneficial and valuable effects of 
gene therapy with the goal of TP53 as a 
complementary therapy in cancers. Studies in 1997 
and 1998 found that p53 plays a critical role in 
controlling of the cell cycle since its normal function 
not forces the cell to stop the cell cycle so that it can 
enter a period of interruption to repair the DNA 
damage. If the cell could not repair damage to the cell, 
it would commit suicide to prevent mutations in the 
cells [6], [7]. Injury to the TP53 gene occurs during the 
life-span of the individual, but in rare cases, involved 
about 1% the cases of sporadic BCs [15], [16], [17], 
[18]. In a study in 2009, numbers of 1836 articles from 
1986 to 2008 were reviewed for involved genes in BC 
[3]. In the TP53 gene, the importance of codon 72 has 
been shown to identify changes in the various 
populations. This codon site is within the active site of 
the p53 protein. In studies conducted in 2006 and 
2007, it was found that using some of the pathological 
characteristics of BC, such as the tumor size, negative 
status of PR, positive status of the lymph nodes and 
high differentiation can be predicted that a patient will 
be more likely to develop metastasis [19], [20], [21], 
[22]. Other studies showed significant differences in 
the prevalence of codon 72 in TP53 polymorphism in 
endometriosis in a Brazilian population [23].  
The present study showed that the frequency 
of changes in codon 72 of the TP53 gene in the 
studied population was common and totally 76.7 % of 
the studied patients had this change. Also, there are 
associations between a polymorphism at microRNA 
binding site in BRCA2 with BC susceptibility [24], [25]. 
Also, there are an association of polymorphisms in 
FCGR2A and FCGR3A with a degree of Trastuzumab 
in the Adjuvant treatment of ERBB2/HER2- positive 
BC [26]. A study results at 2017 showed a significantly 
association between six SNPs including FGFR2 
(rs2981582), HCN1 (rs981782), MAP3K1 (rs889312), 
TOX3 (rs3803662), ZNF365 (rs10822013), and 
RAD51B (rs3784099), with breast cancer risk [25]. A 
study in South Korea on persons with gastric cancer 
that treated with cisplatin and paclitaxel chemotherapy 
indicated that rs1042522 (G/G and C/G) genotypes 
compared to rs1042522 (C;C) were significantly 
associated with lower response rate to the 
chemotherapy treatment (35.7 vs. 66.7%, p-value 
0.019) [28]. Another study at 2014 on patients with 
NSCLC showed that G/G genotype of rs1042522 was 
more resistant to the first-line chemotherapy drugs, 
such as cisplatin [29]. In the present study, we 
evaluated all changes in studied amplicon compared 
to the control samples by sequencing method. The 
results of our study indicated the relationship between 
the rs1042522 polymorphism with age, BMI, 
metastasis, positive status of PR and ER and 
treatment response rate in these patients (Table 3). 
Table 3: Some demographic features of the studied samples 
and differences in genotypes distribution of TP53 at codon 72 
in this study (P value < 0.05) 
Dif. Cc 
pro(%) 
Dif. Gc arg 
/pro(%) 
Dif. Gg 
arg(%) 
No. Of 
patients 
(%) 
Total 
no. 
Detail Characteristic 
-22.06 
-1.48 
2.94 
23.52 
-38.24 
-11.17 
11.76 
38.23 
-16.8 
-10.3 
8.82 
14.070 
23.52 
76.47 
8 
26 
<40 
>40 
Age 
-13.24 
-22.06 
-7.36 
11.76 
2.94 
17.64 
-26.48 
-47.06 
-32.36 
23.52 
2.94 
17.64 
-10.3 
-13.24 
-22.06 
11.76 
2.94 
8.82 
47.05 
8.82 
44.11 
16 
3 
15 
No 
<52 
>52 
Menopausal 
age 
-19.12 
-1.48 
5.88 
23.52 
-38.24 
-14.71 
11.76 
35.29 
-19.12 
-7.36 
5.88 
17.64 
23.52 
76.47 
8 
26 
Positive 
Negative 
Er status 
-19.12 
-1.48 
5.88 
23.52 
-38.24 
-14.71 
11.76 
35.29 
-19.12 
-7.36 
5.88 
17.64 
23.52 
76.47 
8 
26 
Positive 
Negative 
Pr status 
-13.24 
-7.36 
11.76 
17.64 
-29.42 
23.43 
20.58 
26.47 
-13.24 
-13.24 
11.76 
11.76 
44.11 
55.88 
15 
19 
Positive 
Negative 
Her2 status 
-22.06 
-1.48 
2.94 
23.52 
-41.18 
-8.83 
8.82 
41.17 
-19.12 
-7.36 
5.88 
17.64 
17.64 
82.35 
6 
28 
Yes 
No 
Metastasis 
-19.12 
4.41 
5.88 
29.41 
-41.18 
-8.83 
8.82 
41.17 
-22.06 
-16.8 
2.94 
8.82 
17.64 
88.23 
6 
30 
Chemo-
therapy+ 
Chemo-
therapy- 
Treatment  
-22.06 
1.47 
2.94 
26.47 
-41.18 
-11.77 
8.82 
38.23 
-16.8 
-10.3 
8.82 
14.70 
20.58 
79.41 
7 
27 
>22 
<22 
Bmi 
-13.24 
-7.36 
11.76 
17.64 
-29.42 
-47.06 
20.58 
2.94 
-16.8 
-13.24 
8.82 
11.76 
41.17 
58.82 
14 
20 
<0.8 
>0.8 
Whr (waist to 
hip ratio) 
1.48 26.47 0 50 -1.48 23.52 100 34 Invasive 
ductal 
carcinoma 
Histological 
type 
dif: the difference between expected and observed genotypes in HWE equation; p2: GG, 2pq: G/C, q2: CC) 
 
In the present study, we investigated that 
rs1042522 SNP may be associated with susceptibility 
to BC among Iranian women with higher age and BMI. 
The distribution of C Allele in individuals with age of 
higher than 40 years was 1.2 times more than lower 
ages. Also, the frequency of G allele is associated to 
lower BMI and WHR. Our data showed there was a 
direct association between C/G and C/C genotype of 
rs1042522 with a negative response to chemotherapy 
(1.13 times). 
Based on the new issue of “personalised 
medicine” in modern medicine, patients can be treated 
according to their molecular feathers. Therefore, it can 
be inferred that determination of TP53 variants for BC 
patients is suitable before the starting the treatment 
protocol. Cancer is a multi-factorial disease and, in 
addition to genetic, environmental factors such as 
smoking, family income etc. also contributes to its 
development. The results of this study revealed the 
lack of significant correlation between these factors 
including family income, Educational level, the age of 
marriage and cigarette smoking with the studied 
polymorphism (data not shown). However, any of 
these factors may be effective in the overall survival 
rate and severity of the disease.  
However any of these factors may be 
effective in overall survival rate and severity of the 
disease. Performance of molecular diagnostic tests for 
the evaluation of cancer genes in medical centers is 
critical. Hence, the determination of polymorphism in 
the mentioned codon can be used as a potential 
candidate diagnostic marker for high risk BC. 
 
 
Acknowledgements  
 
The authors of this article thank for the 
research and technology deputy of Arak University of 
medical sciences. 
 Anoushirvani et al. Association of Rs1042522 SNP with Clinicopathologic Factors Of Breast Cancer Patients in the Markazi Province of Iran 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Dec 20; 6(12):2277-2282.                                                                                                                                                2281 
 
Author contributions 
 
The first two authors contributed to this study 
and have equal role: clinical sample preparation; AA: 
designed study, performed the experiments, analysed 
data, interpreted data and manuscript preparation; TA: 
clinical sample preparation, SA, MA and MS: 
performed the experiments  
 
 
References 
 
1. Yarnold J. Early and locally advanced breast cancer: diagnosis 
and treatment National Institute for Health and Clinical Excellence 
guideline 2009. Clinical Oncology. 2009; 21(3):159-60. 
https://doi.org/10.1016/j.clon.2008.12.008 PMid:19167201  
2. Israyelyan AH. The development of molecular diagnostics for 
breast cancer. 2003.  
3. McCafferty MP, Healy NA, Kerin MJ. Breast cancer subtypes 
and molecular biomarkers. Diagnostic Histopathology. 2009; 
15(10):485-9. https://doi.org/10.1016/j.mpdhp.2009.07.002 
 
4. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, 
Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, 
Ellis IO, Tavaré S. MicroRNA expression profiling of human breast 
cancer identifies new markers of tumor subtype. Genome biology. 
2007; 8(10):R214. https://doi.org/10.1186/gb-2007-8-10-r214 
PMid:17922911 PMCid:PMC2246288 
 
5. Ahmadi A, Khansarinejad B, Hosseinkhani S, Ghanei M, Mowla 
SJ. miR-199a-5p and miR-495 target GRP78 within UPR pathway 
of lung cancer. Gene. 2017 Jul 15;620:15-22. 
https://doi.org/10.1016/j.gene.2017.03.032 PMid:28363780  
 
6. Joensuu K. Tumor Dormancy in Breast Cancer. 2012. 
 
7. Mehta D, Gonik M, Klengel T, Rex-Haffner M, Menke A, Rubel J, 
Mercer KB, Pütz B, Bradley B, Holsboer F, Ressler KJ. Using 
polymorphisms in FKBP5 to define biologically distinct subtypes of 
posttraumatic stress disorder: evidence from endocrine and gene 
expression studies. Archives of general psychiatry. 2011 Sep 
5;68(9):901-10. https://doi.org/10.1001/archgenpsychiatry.2011.50 
PMid:21536970 PMCid:PMC3686481 
 
8. Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, 
Mansouri F, Modarressi MH. Expression analysis of MiR-21, MiR-
205, and MiR-342 in breast cancer in Iran. Asian Pacific Journal of 
Cancer Prevention. 2012; 13:873-877. 
https://doi.org/10.7314/APJCP.2012.13.3.873 PMid:22631664  
 
9. Doosti A, Dehkordi PG, Davoudi N. A p53 codon 72 
polymorphism associated with breast cancer in Iranian patients. 
African Journal of Pharmacy and Pharmacology. 2011; 5(10):1278-
1281. https://doi.org/10.5897/AJPP10.394 
 
10. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 
codon 72 polymorphism and MDM2 SNP309 with clinical outcome 
of advanced nonsmall cell lung cancer. Cancer: Interdisciplinary 
International Journal of the American Cancer Society. 
2008;113(4):799-807. https://doi.org/10.1002/cncr.23668 
PMid:18618574  
 
11. Reiling E, Lyssenko V, Boer JM, Imholz S, Verschuren WMM, 
Isomaa B, Tuomi T, Groop L, Dollé ME. Codon 72 polymorphism 
(rs1042522) of TP53 is associated with changes in diastolic blood 
pressure over time. European Journal of Human Genetics. 2012; 
20(6):696. https://doi.org/10.1038/ejhg.2011.240 PMid:22189267 
PMCid:PMC3355249 
 
12. Asadi M, Shanehbandi D, Zarintan A, Pedram N, Baradaran B, 
Zafari V, Shirmohamadi M, Hashemzadeh S. TP53Gene Pro72Arg 
(rs1042522) Single Nucleotide Polymorphism as Not a Risk Factor 
 
for Colorectal Cancer in the Iranian Azari Population. Asian Pacific 
journal of cancer prevention: APJCP. 2017; 18(12):3423. 
PMid:29286614  
13. He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H. 
The TP53 gene rs1042522 C> G polymorphism and 
neuroblastoma risk in Chinese children. Aging (Albany NY). 2017; 
9(3):852. https://doi.org/10.18632/aging.101196 PMid:28275206 
PMCid:PMC5391235 
 
14. Jahani M, Anoushirvani AA, Shahi F, Azimaraghi O. Abducens 
nerve palsy as initial presentation of Burkitt Lymphoma during 
Pregnancy Post–Cesarean abducens nerve paresis and 
Headache. International Journal of Hematology-Oncology and 
Stem Cell Research. 2009; 3(1):37-9. 
 
15. De Jong MM, Nolte IM, Te Meerman GJ, Van der Graaf WTA, 
Oosterwijk JC, Kleibeuker JH, Schaapveld M, De Vries EGE. 
Genes other than BRCA1 and BRCA2 involved in breast cancer 
susceptibility. Journal of medical genetics. 2002; 39(4):225-242. 
https://doi.org/10.1136/jmg.39.4.225 PMid:11950848 
PMCid:PMC1735082 
 
16. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor 
suppressor genes in breast cancer: potential diagnostic and 
therapeutic applications. The oncologist. 2004; 9(4):361-377. 
https://doi.org/10.1634/theoncologist.9-4-361 PMid:15266090  
 
17. Shojaei S, Gardaneh M, Rahimi Shamabadi A. Target points in 
trastuzumab resistance. International journal of breast cancer. 
2012; 2012. 
 
18. Cristofanilli M, Hortobagyi GN. Molecular targets in breast 
cancer: current status and future directions. Endocrine-related 
cancer. 2002; 9(4):249-266. https://doi.org/10.1677/erc.0.0090249 
PMid:12542402  
 
19. Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, 
Howell A, Newman WG, Cuzick J. FH-risk study Group. The impact 
of a panel of 18 SNPs on breast cancer risk in women attending a 
UK familial screening clinic: a case–control study. Journal of 
medical genetics. 2017; 54(2):111-113. 
https://doi.org/10.1136/jmedgenet-2016-104125 PMid:27794048  
 
20. Furrer D, Lemieux J, Côté MA, Provencher L, Laflamme C, 
Barabé F, Jacob S, Michaud A, Diorio C. Evaluation of human 
epidermal growth factor receptor 2 (HER2) single nucleotide 
polymorphisms (SNPs) in normal and breast tumor tissues and 
their link with breast cancer prognostic factors. The Breast. 2016; 
30:191-196. https://doi.org/10.1016/j.breast.2016.09.014 
PMid:27788409  
 
21. Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, 
Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, Baynes 
C. Association of breast cancer risk with genetic variants showing 
differential allelic expression: Identification of a novel breast cancer 
susceptibility locus at 4q21. Oncotarget. 2016; 7(49):80140. 
https://doi.org/10.18632/oncotarget.12818 PMid:27792995 
PMCid:PMC5340257 
 
22. Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, 
Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr 
A. The impact of ERBB-family germline single nucleotide 
polymorphisms on survival response to adjuvant trastuzumab 
treatment in HER2-positive breast cancer. Oncotarget. 2016; 
7(46):75518. https://doi.org/10.18632/oncotarget.12782 
PMid:27776352 PMCid:PMC5342757 
 
23. Camargo-Kosugi CMD, D'Amora P, Kleine JP, Carvalho CVD, 
Sato H, Schor E, Silva ID. TP53 gene polymorphisms at codons 
11, 72, and 248 and association with endometriosis in a Brazilian 
population. Genet Mol Res. 2014; 13(3):6503-11. 
https://doi.org/10.4238/2014.August.26.1 PMid:25177931  
 
24. Cao J, Luo C, Yan R, Peng R, Wang K, Wang P, Ye H, Song 
C. rs15869 at miRNA binding site in BRCA2 is associated with 
breast cancer susceptibility. Medical Oncology. 2016; 33(12):135. 
https://doi.org/10.1007/s12032-016-0849-2 PMid:27807724  
 
25. Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, 
Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain 
SM. Association of polymorphisms in FCGR2A and FCGR3A with 
degree of trastuzumab benefit in the adjuvant treatment of 
ERBB2/HER2–positive breast cancer: analysis of the NSABP B-31 
 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2282                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
trial. JAMA oncology. 2017; 3(3):335-341. 
https://doi.org/10.1001/jamaoncol.2016.4884 PMid:27812689 
PMCid:PMC5344747 
26. Anoushirvani AA, Ahmadi A, Aghabozorgi R, Khalili S, Sahraei 
M, Fereydouni T, Khademi Z. Gengenotypic Evaluation of Hsa-
miR-433-3p Binding Site in the Regulatory Region of TYMS in 
Breast Cancer Patients. AMUJ. 2018; 1-9 
 
27. Yi-Chen H, Shih-Hsin T, Chien-Tien S, Er-Chieh C, Chih-
Hsiung W, Mao-Chih H, Shiyng-Yu L, Yun-Ru L, Chin-Sheng H, 
Hung-Yi C. A polygenic risk scores for breast cancer risk in a 
Taiwanese population. Breast cancer research and treatmen. 
2017; 163(1):131-138. https://doi.org/10.1007/s10549-017-4144-5 
PMid:28205043  
 
28. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim 
 
MK, Lee KH, Hyun MS, Lee WS, Sohn CH. TP53 codon 72 
polymorphism associated with prognosis in patients with advanced 
gastric cancer treated with paclitaxel and cisplatin. Cancer 
chemotherapy and pharmacology. 2009; 64(2):355-60. 
https://doi.org/10.1007/s00280-008-0879-3 PMid:19052714  
29. Zheng D, Chen Y, Gao C, Wei Y, Cao G, Lu N, Hou Y, Jiang X, 
Wang J. Polymorphisms of p53 and MDM2 genes are associated 
with severe toxicities in patients with non-small cell lung cancer. 
Cancer biology & therapy. 2014; 15(11):1542-51. 
https://doi.org/10.4161/15384047.2014.956599 PMid:25482940 
PMCid:PMC4623062 
 
 
